Moleculin Biotech, Inc.

As of April 11, 2025, the technical trend is mildly bearish with weak strength, indicated by bearish weekly MACD and KST, mixed RSI signals, and bearish moving averages, suggesting limited bullish momentum despite some potential for recovery in the longer term.

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on cancer treatments, with a market cap of $9.41 million and a recent net profit of -$6 million. The company operates in the Pharmaceuticals & Biotechnology industry and has no dividend yield or positive earnings.

As of Jun 18, Moleculin Biotech, Inc. has a market capitalization of 9.41 million and reported net sales of 0.00 million with a net profit of -23.23 million over the last four quarters. The balance sheet shows shareholder's funds of 5.98 million and total assets of 16.93 million.